- Flumatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: An OpenLabel, Multi-Center StudyWen, Ziyu; Zhao, Ying; Li, Guowei; Su, YongZhong; Chen, FeiHeng; Tao, HongFang; Zheng, ZhengJin; Lin, Wuqiang; Chen, Xiuli; Meng, Meili; Yu, Lian; Chen, LongTian; Huang, JianQing; Wu, Guocai; Zhao, Mengxia; Liu, Zhenfang; Zhu, Hongqian; Jiang, Yirong; Liu, Qifa; Liu, Xiaoli; Xu, Na65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Safety and Efficacy of Flumatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to ImatinibLiu, Yuntao; Yang, Yunfan; Sun, Hui; Meng, Li; Lin, Hai; Chen, Chunyan; Hu, Jianda; Shen, Xuliang; Duan, Minghui; Zhang, Yanli; Abulaiti, Dilinazi; Wang, Jinghua; Zhu, Hongqian; Hua, Luoming; Leng, Qing; Zhang, Chun; Sun, Lili; Li, Weiming; Zhu, Huanling; Liu, Bingcheng; Wang, Jianxiang65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Flumatinib for the Treatment of Adult Patients with Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia: Results from Real-World DataZhou, Xuan; Xu, Na; Wen, Ziyu; Liang, Hanyin; Luo, Dongmei; Chen, Hong; He, Zherou; Gao, Zicheng; Wang, Qiang; Xu, Dan; Liu, Xiaoli; Liu, Qifa65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
会议论文
Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
14阅读
